{"entity":{"id":"nct01310894","kind":"trial","name":"Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance","aka":[],"tldr":"A phase 3 trial of Padeliporfin in Prostate cancer, run by Steba Biotech S.A., completed.","summary":"Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance is a phase 3 interventional study registered as NCT01310894 by Steba Biotech S.A., with 413 participants recorded, started 2011-02 and reaching its primary completion in 2015-06. Interventions recorded: TOOKAD® Soluble. Conditions recorded: Prostate Cancer.\n\nLinked to the drug Padeliporfin because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT01310894","url":"https://clinicaltrials.gov/study/NCT01310894"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["padeliporfin"],"companies":["steba-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01310894","phase":"3","setting":"A European Randomised Phase 3 Study to Assess the Efficacy and Safety of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance","sponsor":"Steba Biotech S.A.","enrolled":413,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01310894/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"padeliporfin","kind":"drug","name":"Padeliporfin","route":"/drugs/padeliporfin/"}],"company":[{"id":"steba-biotech","kind":"company","name":"Steba Biotech","route":"/companies/steba-biotech/"}]}}